ClinicalTrials.gg
RecruitingNCT06827470Updated Dec 4, 2025

Establishing a Controlled Human Infection Model of Pertactin-deficient Bordetella Pertussis

A Phase 1 interventional study of Biological: Bordetella pertussis J820 in Pertussis (Whooping Cough), sponsored by Dalhousie University. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Dalhousie University · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Whooping Cough with a site in Canada — 1 open to participants now, 2 under way, none of them phase 3. Whooping Cough · Canada.

Planned enrollment
17th of 18
60 · median 548
Started
2025
the only one that year
Phase 1
3 of 21
1 open now
Registered
21st of 21
by date
Lead sponsor
3 of 21
Dalhousie University

Among the 21 studies in Whooping Cough with a site in Canada, this one is the 17th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 1, and was the 21st registered.

Whooping Cough

291 studies on the registry are indexed under Whooping Cough; 24 are open to participants now.

Browse Whooping Cough studies →

Open to participants now

1 of the 21 studies in Whooping Cough with a site in Canada is open now.

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 14 Whooping Cough studies recruiting now, 2 (14%) set no upper age limit and 11 (79%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Whooping Cough with a site in Canada, or all of them as a file.
02

Study summary

The overall goal of this study is to establish a PRN-deficient pertussis Controlled Human Infection Model (CHIM) that represents currently circulating isolates, in the context of a North American exposure (vaccination and infection) pedigree.

03

Conditions studied

  • Pertussis (Whooping Cough)

Browse trials for

Keywords

  • Bordetella pertussis
  • Pertussis
  • Whooping cough
  • Controlled human infection model
  • Human challenge
  • Phase 1 clinical trial
  • Immune response
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for the study, each participant must satisfy ALL of the following criteria:

  1. Age 18-50 years, inclusive.
  2. Good general health status, as determined by history and physical examination conducted no longer than 30 days prior to the challenge.
  3. Participants who, in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g., complete Diary Cards, return for follow-up visits).
  4. Written obtained from the participant.
  5. If a cis woman and/or gender divergent person is at risk of becoming pregnant has practiced adequate for 28 days prior to challenge and has a negative pregnancy test on the day before B. pertussis challenge and has agreed to continue adequate contraception until 60 days after inoculation.

Risk of pregnancy is defined as any individual assigned female at birth or with reproductive capacity who is sexually active with individuals with sperm-producing capabilities. Individuals who have received the following are considered to not have reproductive capacity:

  • Documented hysterectomy
  • Documented bilateral salpingectomy
  • Documented bilateral oophorectomy
  • Documented and current bilateral tubal ligation or occlusion
  • Credible self-reported history of diagnosed infertility
  • Hormone therapy (e.g., testosterone), provided it is administered consistently and medically assessed as sufficient to reduce pregnancy such that ovulation has ceased
  • Any other condition, as determined by the Principal Investigator, that would render an individual incapable of becoming pregnant

Adequate contraception is defined as a contraceptive method with a failure rate of \<1% per year when used consistently and correctly and, when applicable, in accordance with the product label. Examples include the following:

  • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal
  • Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable
  • Intra-uterine device (IUD) with or without hormonal release
  • Vasectomized partner, if this is the participant's sole partner and the partner has received a medical assessment of the surgical success
  • Credible self-reported history of abstinence for at least 28 days prior to challenge

Exclusion criteria

Exclusion Criteria:

Participants with ANY of the following criteria at the time of screening will be excluded:

  1. Underlying chronic medical condition requiring ongoing follow-up and monitoring by a physician (e.g., diabetes, seizure disorder).
  2. Underlying cardiac and/or pulmonary disease including hypertension, angina, prior myocardial infarction, asthma, emphysema, chronic bronchitis, and pulmonary tuberculosis.
  3. Moderate or severe symptoms of health anxiety, anxiety, and mood symptoms. Self-reported current diagnosis of a major psychiatric illness, including a schizophrenia spectrum disorder, bipolar disorder, posttraumatic stress disorder, obsessive compulsive disorder, substance use, or eating disorder.
  4. on (EKG).
  5. History of everyday smoking/vaping in the last 2 years and/or current smoking/vaping more than once per week.
  6. Pregnant (known before or established at the time of screening using a urine-based test) or breastfeeding.
  7. (with /AIDS-positive or receiving immunosuppressive therapy involving ) or with any medical condition or medication that leads to a compromised immune system.
  8. Positive for or C by blood test.
  9. Vaccinated against pertussis within previous 5 years and/or >7 cumulative doses from infancy to date of screening.
  10. Reported history of laboratory-confirmed pertussis infection, including having been exposed to B. pertussis in a Controlled Human Infection Model
  11. Antibody titer to pertussis toxin >20 IU/mL (2x the lower limit of quantification (LLOQ)).
  12. Detection of B. pertussis in nasal samples prior to challenge using culture isolation and/or PCR detection, or detection of other respiratory infection.
  13. Living or working with (any form of close contact) any of the at-risk/vulnerable groups who are not up to date on their vaccination, specifically children \<1 year of age, pregnant woman who have not yet received their maternal Tdap vaccine, immunocompromised individuals, adults >65 years of age who have not received a dose of Tdap vaccine within the past 10 years, or other at risk persons, as applicable, up to Day 57.

    Note: Household members whose vaccination is not current will be offered or directed to a pertussis-containing vaccine, as recommended and funded by the Nova Scotia Department of Health and Wellness.

  14. Known allergy to macrolides including azithromycin or erythromycin, history of Clostridium difficile within last 2 months.
  15. Any to receiving azithromycin.
  16. Taking any systemic antibiotic currently or within the previous 2 weeks.
  17. Currently taking terfenadine, astemizole, theophylline, or cimetidine.
  18. Poor venous access, as defined by inability to obtain venous blood after 3 venipuncture attempts.
  19. Recent (within 6 months) nasal or sinus surgery, recent use of intranasal steroids (4 weeks), or diagnosis with nasal polyps.
  20. Receipt of any drug or vaccine within 6 months prior to challenge. An investigational vaccine is defined as a vaccine that is still being tested in clinical trials or one that has not yet been authorized for use in Canada for administration by public vaccine programs.
  21. Receipt of any authorized vaccines within 2 weeks prior to challenge with B. pertussis in this study. (This is to avoid attributing any AEs from these vaccines to the B. pertussis challenge, which would skew the study results.)
  22. Previous moderate or severe respiratory infection that required hospitalization.
  23. Head trauma (e.g., fracture of the cribriform plate) within 1 year of screening.
  24. Any other finding that the Investigator considers will make the participant unsuitable for the study or unable to comply with the study requirements.
  25. Symptoms indicative of acute respiratory illness (such as fever, cough, difficulty breathing) identified during the physical examination done on Day -1 (check-in) or Study Day 1 before a participant is challenged.
  26. History of Bell's Palsy and/or facial paralysis.
  27. Receipt of facial cosmetic filler in the past 3 months.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group 1: Dose Number 5 (10^5)

    Biological: Biological: Bordetella pertussis J820

  • Experimental
    Group 2: Dose Number 7 (10^6)

    Biological: Biological: Bordetella pertussis J820

  • Experimental
    Group 3: Dose Number 9 (10^7)

    Biological: Biological: Bordetella pertussis J820

  • Experimental
    Group 4: Dose Number 11 (10^8)

    Biological: Biological: Bordetella pertussis J820

  • Experimental
    Group 5: Dose Number 13 (10^9)

    Biological: Biological: Bordetella pertussis J820

Interventions

  • BiologicalBiological: Bordetella pertussis J820

    Intranasal inoculation of Bordetella pertussis J820 in each naris on Day 1 of the study.

06

What researchers measure

Primary outcomes

  1. Primary Outcome Measures

    Establish a PRN-deficient pertussis CHIM that identifies the lowest challenge dose that successfully \& safely infects nearly all (≥85%) participants challenged (HID) \& produces the highest achievable rate of symptomatic infection (HSD), including cough, using an adaptive dose response design. This is contingent upon determining each participant's clinical outcome post-challenge to compute the rate of symptomatic infection \& rate of overall infection per dose group, based on outcomes for all participants receiving that dose. As a derived variable, clinical outcomes will be measured/determined using programmed case definitions previously designed to emulate the natural course of early pertussis disease following experimentally induced pertussis infection. Clinical outcome measures include: 1. B. pertussis lab testing of samples (culture, PCR, serology) 2. Clinical assessments (safety bloods, physical exams, DCs, symptom self-reporting).

    Time frame: Study Day 1 up to Study Day 29

Secondary outcomes

  1. Secondary Outcome Measures

    • To measure the rate of cough and describe the clinical presentation via: 1. Self-reporting 2. Clinical assessment

    Time frame: Study Day 1 up to Study Day 29

  2. Secondary Outcome Measures

    • To evaluate the immune response following challenge associated with infection via: 1\. Humoral immune responses (analyte; unit; sample; technique): A) Anti-PT Antibodies; IU/mL; Serum; ELISA B) Anti-FHA Antibodies; IU/mL; Serum; ELISA C) Anti-PRN Antibodies; IU/mL; Serum; ELISA D) Anti-FIM Antibodies; EU/mL; Serum; ELISA

    Time frame: Day 1 up to Study Day 181

  3. Secondary Outcome Measure

    • To evaluate the immune response following challenge associated with infection via: 2\. Cellular \& Cellular-mediated immune responses Cellular: A) Eotaxin-2, Perfornin, Granzyme-A \& Granzyme-B; all pg/mL, by nasal wash using Luminex Cellular-mediated: A) Neutrophil CD16+, B cell CD19+, T Cell CD4+, T cells CD8+, Mucosal associated invariant T cell(MAIT) cells, NK cell CD3-CD56+, Monocyte CD14+, Eosinophil Siglec8+, gamma delta T cell; all % \& absolute count, by whole blood \& nasal swab using Flow cytometry

    Time frame: Time Frame: Day 1 up to Study Day 181

  4. Secondary Outcome Measures

    • To explore the time course of azithromycin therapy in clearing infection and/or symptoms, via testing during treatment as applicable via: 1\. B. pertussis laboratory testing of samples (culture, PCR): A) The mean number of days to culture negativity (i.e., bacterial count of zero in both NW and NPA samples) in days (with a 95% confidence interval) following treatment. B) The mean number of days to PCR negativity (i.e., PCR negative for each of the targets, that is IS481 and ptxS1 in both NW and NPA samples in days (with a 95% CI) following treatment. C) The cumulative proportion of participants that are negative by day following treatment by culture and PCR.

    Time frame: Study Day 1 up to Study Day 29

  5. Secondary Outcome Measure

    • To explore the time course of azithromycin therapy in clearing infection and/or symptoms, via testing during treatment as applicable via: 2\. Clinical assessments (as needed): A) The mean number of days to symptom resolution (i.e., no reporting/detection of symptoms and/or signs) in days (with a 95% confidence interval) following treatment. B) The cumulative proportion of participants with resolved pertussis symptoms by day following treatment.

    Time frame: Time Frame: Study Day 1 up to Study Day 29

Other outcomes

  1. Exploratory Outcome Measures

    • To recommend optimal time points for the collection of biological specimens that facilitate studying mucosal and systemic immune responses to pertussis infection and/or vaccination will be measured via: 1\. Collective review of the results from all laboratory testing conducted to measure the previous outcomes.

    Time frame: Study Day 1 up to Study Day 181

  2. Exploratory Outcome Measures

    • Contributing samples from the study to the CDC biorepository will be measured via: 1\. Estimating the proportion of samples for which a portion will be submitted to the biorepository.

    Time frame: Study Day 1 Up to Study Day 181

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2025
First posted
Feb 14, 2025
StartActual
Nov 24, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Apr 30, 2027
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06827470
Lead sponsor
Dalhousie University
Responsible party
Sponsor
First posted
Feb 14, 2025
Start date
Nov 24, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Dec 4, 2025

Study contacts

Nick Bartlett
Contact
nicholas.bartlett@iwk.nshealth.ca
902-470-8141
Hannah Munday
Contact
hannah.munday@iwk.nshealth.ca
902-470-8141

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion